Supplementary Data1 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial
Year: 2026
Type: supplementary-materials
Abstract: Supplementary materials
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7172331625
Cites:
Cited by:
Related to:
